Allurion Partners to Offer Discounted Mounjaro Combination Therapy in Argentina
Event summary
- Allurion partners with Bionut and Farmastar to offer discounted Mounjaro for combination therapy with its Smart Capsule in Argentina.
- Study showed 23% average total body weight loss at 12 months using low-dose tirzepatide (2.5mg-5.0mg) with Allurion Smart Capsule.
- No patients discontinued early, and all remained adherent to tirzepatide throughout the study.
- Allurion exploring similar partnerships in other regions to increase GLP-1 accessibility.
The big picture
Allurion's partnership targets the growing obesity epidemic by combining its Smart Capsule with discounted GLP-1 therapy, addressing high discontinuation rates of standalone treatments. This strategy aligns with broader industry trends toward metabolically healthy weight loss solutions and cost-effective combination therapies. The deal underscores the potential for regional partnerships to enhance accessibility and adherence in obesity care.
What we're watching
- Geographic Expansion
- Whether Allurion can successfully replicate this model in other regions.
- Clinical Efficacy
- How sustained weight loss and adherence rates will be in real-world settings.
- Regulatory Dynamics
- The pace at which regulatory approvals will enable broader combination therapy offerings.
Related topics